MA28975B1 - Compositions et procedes de traitement de troubles neurologiques - Google Patents

Compositions et procedes de traitement de troubles neurologiques

Info

Publication number
MA28975B1
MA28975B1 MA29599A MA29599A MA28975B1 MA 28975 B1 MA28975 B1 MA 28975B1 MA 29599 A MA29599 A MA 29599A MA 29599 A MA29599 A MA 29599A MA 28975 B1 MA28975 B1 MA 28975B1
Authority
MA
Morocco
Prior art keywords
compositions
methods
neurodegenerative
neurological disorders
treating neurological
Prior art date
Application number
MA29599A
Other languages
English (en)
Inventor
Dan Frenkel
Ruth Maron
David Burt
Howard L Weiner
Original Assignee
Id Biomedical Corp Quebec
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Id Biomedical Corp Quebec, Brigham & Womens Hospital filed Critical Id Biomedical Corp Quebec
Publication of MA28975B1 publication Critical patent/MA28975B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions qui convienne pour traiter des troubles neurologiques, notamment des troubles neurodégénératifs associés à l'agrégation de protéines délétères, au repliement des protéines aberrant, tels que des maladies amylogéniques du cerveau et/ou, des troubles auto-immuns neurodégénératifs. Cette invention concerne aussi des procédés d'utilisation de ces compositions. En particulier des procédés permettant de traiter un trouble neurodégénératif tel que la maladie d'Alzheimer et un trouble auto-immun neurodégénératif tel que la sclérose en plaques, via l'utilisation de protéosomes et/ou de Glatiramer Acétate, ces GA étant une émulsion submicronique ou une nanoémulsion.
MA29599A 2004-06-25 2006-12-29 Compositions et procedes de traitement de troubles neurologiques MA28975B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58299904P 2004-06-25 2004-06-25

Publications (1)

Publication Number Publication Date
MA28975B1 true MA28975B1 (fr) 2007-11-01

Family

ID=35207559

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29599A MA28975B1 (fr) 2004-06-25 2006-12-29 Compositions et procedes de traitement de troubles neurologiques

Country Status (18)

Country Link
US (1) US20060229233A1 (fr)
EP (3) EP2332569A3 (fr)
JP (2) JP5274011B2 (fr)
KR (2) KR101347105B1 (fr)
CN (2) CN103143011A (fr)
AU (1) AU2005259991B2 (fr)
CA (1) CA2571035A1 (fr)
ES (1) ES2432369T3 (fr)
HK (1) HK1101140A1 (fr)
IL (1) IL179933A (fr)
MA (1) MA28975B1 (fr)
MX (1) MXPA06015096A (fr)
NO (1) NO20070460L (fr)
NZ (2) NZ578727A (fr)
RU (2) RU2387453C2 (fr)
SG (2) SG153871A1 (fr)
WO (1) WO2006004749A2 (fr)
ZA (1) ZA200610661B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4966661B2 (ja) 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007065167A1 (fr) * 2005-12-02 2007-06-07 The Johns Hopkins University Utilisation de doses elevees de medicaments comprenant de l'oxazaphosphorine pour le traitement de troubles immunitaires
WO2008034071A2 (fr) 2006-09-15 2008-03-20 The Johns Hopkins University Procédé d'identification de patients approprié pour un traitement à la cyclophosphamide par de fortes doses
WO2008034076A2 (fr) 2006-09-15 2008-03-20 The Johns Hopkins University Utilisation de cyclophosphamide à doses élevées en combinaison avec des thérapeutiques d'immunisation dans le traitement anticancer
WO2008034074A2 (fr) 2006-09-15 2008-03-20 The Johns Hopkins University Utilisation de cyclophosphamide à doses élevées en combinaison avec des vaccins anti-idiotypiques dans le traitement anticancéreux
US7629135B2 (en) * 2006-12-22 2009-12-08 The Board Of Trustees Of The University Of Illinois Toll-like receptor agonists and antagonists and methods of use thereof
JP2010536907A (ja) 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
CA2701172A1 (fr) * 2007-10-01 2009-04-09 The Johns Hopkins University Methodes de traitement de troubles neurologiques auto-immuns utilisant le cyclophosphamide
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067699A2 (fr) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Procédés pour dispenser un système de soin pour un régime à base de médicament de type oxazaphosphorine
US10383887B2 (en) * 2008-02-20 2019-08-20 New York University Preventing and treating amyloid-beta deposition by stimulation of innate immunity
WO2009132244A1 (fr) * 2008-04-25 2009-10-29 Id Biomedical Corporation Of Quebec Procédés de préparation de compositions immunogènes
WO2009146301A1 (fr) * 2008-05-27 2009-12-03 Yale University Le tgf-β : une nouvelle cible thérapeutique pour la maladie d'alzheimer
ES2612001T4 (es) * 2009-08-20 2018-02-07 Yeda Research & Development Company, Ltd. Terapia de baja frecuencia con acetato de glatirámero
JP5792276B2 (ja) 2010-03-31 2015-10-07 トムソン ライセンシングＴｈｏｍｓｏｎ Ｌｉｃｅｎｓｉｎｇ ビデオデータのトリック再生
US9510758B2 (en) 2010-10-27 2016-12-06 The General Hospital Corporation Apparatus, systems and methods for measuring blood pressure within at least one vessel
JP2014530819A (ja) 2011-10-10 2014-11-20 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーに対する臨床的応答性を予測するために有用な一塩基多形
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10493122B2 (en) 2014-03-17 2019-12-03 Mapi Pharma Ltd. Sublingual delivery of glatiramer acetate
EP3458036B1 (fr) * 2016-05-20 2023-08-23 Cedars-Sinai Medical Center Traitement ou prévention de la maladie d'alzheimer et d'états associés
RU2629385C1 (ru) * 2016-09-29 2017-08-29 Владимир Федорович Корсун Способ лечения рассеянного склероза
GB201916185D0 (en) * 2019-11-07 2019-12-25 Randox Laboratories Ltd Biomarker of drug-induced cellular toxicity and depression

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JP3836874B2 (ja) * 1994-02-24 2006-10-25 ノババックス インコーポレイテッド 免疫アジュバントとして少ラメラ脂質小胞を含むワクチン
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
EA199800208A1 (ru) 1995-09-18 1998-10-29 Юнайтед Стэйтс Арми Медикал Ресерч Материэл Комманд (Юсамрмк) Усовершенствованные способы изготовления нековалентно комплексированных и поливалентных вакцин протеосомной подгруппы
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6703015B1 (en) * 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US6905686B1 (en) * 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP2000154148A (ja) * 1998-11-20 2000-06-06 Toray Ind Inc インターフェロンβをアジュバントとするワクチン
US20020052311A1 (en) * 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
WO2001018169A2 (fr) * 1999-09-03 2001-03-15 Ramot University Authority For Applied Research & Industrial Development Ltd. Agents et compositions et procedes utilisant lesdits agents et lesdites compositions pour le diagnostic et/ou le traitement ou la prevention des maladies formant des plaques.
DE60112718T2 (de) * 2000-01-20 2006-06-29 Yeda Research And Development Co., Ltd. Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
DE60121136T2 (de) * 2000-02-15 2007-06-06 Id Biomedical Corporation Of Quebec, Ville St. Laurent Proteasom-influenzavirus-impfstoffzusammensetzung
EP1261361B1 (fr) * 2000-02-18 2006-06-14 Yeda Research And Development Company, Ltd. Formes posologiques a administration par voie orale, nasale et pulmonaire du copolymere 1 (acetate de glatiramer)
AU783144B2 (en) * 2000-02-21 2005-09-29 H. Lundbeck A/S Novel method for down-regulation of amyloid
EP1372706B1 (fr) * 2001-03-09 2010-12-01 ID Biomedical Corporation of Quebec Adjuvant de vaccin proteosome-liposaccharide
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (ja) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック 麻疹サブユニットワクチン
JP4966661B2 (ja) * 2003-10-22 2012-07-04 アイディー バイオメディカル コーポレイション オブ ケベック 生得的免疫およびアレルギー性免疫を活性化させるための組成物および方法
WO2005041933A1 (fr) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries, Ltd. Nanoparticules pour la delivrance de medicaments
AU2005319716A1 (en) * 2004-06-30 2006-06-29 Id Biomedical Corporation Of Quebec Vaccine compositions for treating coronavirus infection
SI1797109T1 (sl) * 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe

Also Published As

Publication number Publication date
RU2010103240A (ru) 2011-08-10
WO2006004749A3 (fr) 2006-04-20
KR20070048703A (ko) 2007-05-09
MXPA06015096A (es) 2007-05-09
SG186686A1 (en) 2013-01-30
CN103143011A (zh) 2013-06-12
US20060229233A1 (en) 2006-10-12
EP2332569A2 (fr) 2011-06-15
KR101347562B1 (ko) 2014-01-03
WO2006004749A2 (fr) 2006-01-12
CN101039691B (zh) 2013-07-31
KR101347105B1 (ko) 2014-01-02
HK1101140A1 (en) 2007-10-12
AU2005259991A1 (en) 2006-01-12
EP2332569A3 (fr) 2011-09-14
EP2332570A1 (fr) 2011-06-15
SG153871A1 (en) 2009-07-29
ES2432369T3 (es) 2013-12-03
NZ578727A (en) 2011-03-31
AU2005259991B2 (en) 2011-05-26
RU2007102698A (ru) 2008-07-27
JP5274011B2 (ja) 2013-08-28
CN101039691A (zh) 2007-09-19
CA2571035A1 (fr) 2006-01-12
ZA200610661B (en) 2008-08-27
EP1761276B1 (fr) 2013-07-24
RU2387453C2 (ru) 2010-04-27
KR20120112885A (ko) 2012-10-11
JP2008504299A (ja) 2008-02-14
IL179933A0 (en) 2007-05-15
EP1761276A2 (fr) 2007-03-14
NO20070460L (no) 2007-03-23
IL179933A (en) 2015-06-30
NZ552075A (en) 2009-08-28
JP2012041351A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
MA28975B1 (fr) Compositions et procedes de traitement de troubles neurologiques
MA30163B1 (fr) Anticorps monoclonaux specifiques pour a beta 1-42 ayant des proprietes therapeutiques
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
WO2002086443A8 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
MA28972B1 (fr) Indazoles, benzothiazoles , benzoisothiazoles, benzisoxazoles, et leur preparation et leurs utilisations
MA30632B1 (fr) Anticorps humanisé
WO2002074240A3 (fr) Diagnostic et traitement d'une maladie ou d'une affection neurologique se fondant sur un anticorps anti-amyloide
WO2000065502A8 (fr) Procedes permettant de traiter un groupe de comptes correspondant a differents produits
WO2003042654A3 (fr) Methodes de criblage a haut debit a parametres multiples
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
AT500379B8 (de) Tau-proteine
GB9619691D0 (en) Antibodies against E-selection
MA30252B1 (fr) Vaccin therapeutique
MA28228A1 (fr) Indoles, 1h-indazoles, 1,2-benzisoxazoles, et 1,2-benzisothiazoles, et leur preparation et utilisation
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
MA27453A1 (fr) Indazoles, benzothiazoles et benzoisothiazoles, leur preparation et leurs utilisations
MA27060A1 (fr) Therapeutique mixte pour le traitement du cancer
HUP0500001A2 (hu) Pramipexol alkalmazása amiotrófiás laterálszklerózis kezelésére
WO2001018550A3 (fr) Determination de proteines de liaison a am et association d'adrenomedulline (am)
MA29227B1 (fr) 4-phenyltetrahydroisoquinoline substituees, leur procedes de fabrication, leur utilisation en tant que medicament et medicament les contenant
ATE504310T1 (de) Neuroprotektive, antithrombotische und anti- entzündliche anwendungen von aktiviertem protein c
MA29218B1 (fr) Nonadepsipeptides acyles sous forme de derives de lysobactine
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
WO2002033114A3 (fr) Interaction proteine-proteine dans des maladies neurodegeneratives
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére